This drug delayed rheumatoid arthritis for years after treatment ended
A long-term study from King's College London shows that a one-year course of the drug abatacept can delay the onset of rheumatoid arthritis by several years in high-risk individuals. While not a cure, the treatment significantly alters the disease trajectory for patients.
Why it matters
This represents a breakthrough in preventative medicine for autoimmune diseases, potentially reducing long-term disability and economic loss for patients.
People at high risk of developing rheumatoid arthritis (RA) may be able to postpone the disease for years with early treatment, according to new research from King's College London. The study found that a one year course of the biologic drug abatacept significantly delayed the onset of rheumatoid arthritis, with benefits continuing long after treatment ended.
The article objectively reports on clinical trial results published in a medical journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in